Revised SPCs: Adcetris (brentuximab vedotin) 50 mg powder for concentrate for solution for infusion

SPCs have been revised to warn that elderly patients may be more susceptible to adverse events such as pneumonia, neutropenia and febrile neutropenia.

Source:

electronic Medicines compendium